Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fan Yang, Ran Meng, Da-Long Zhu
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2020
Materias:	Sodium-glucose cotransporter-2 inhibitors Type 2 diabetes Cardiovascular outcomes Mechanisms of cardiovascular benefits Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/7cdbba4d6c314a6a9f286fa7af3beceb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7cdbba4d6c314a6a9f286fa7af3beceb
record_format	dspace
spelling	oai:doaj.org-article:7cdbba4d6c314a6a9f286fa7af3beceb2021-12-02T14:18:28ZCardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors2095-882X10.1016/j.cdtm.2020.07.002https://doaj.org/article/7cdbba4d6c314a6a9f286fa7af3beceb2020-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X20300645https://doaj.org/toc/2095-882XSodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety.Fan YangRan MengDa-Long ZhuKeAi Communications Co., Ltd.articleSodium-glucose cotransporter-2 inhibitorsType 2 diabetesCardiovascular outcomesMechanisms of cardiovascular benefitsMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 6, Iss 4, Pp 239-245 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Sodium-glucose cotransporter-2 inhibitors Type 2 diabetes Cardiovascular outcomes Mechanisms of cardiovascular benefits Medicine (General) R5-920
spellingShingle	Sodium-glucose cotransporter-2 inhibitors Type 2 diabetes Cardiovascular outcomes Mechanisms of cardiovascular benefits Medicine (General) R5-920 Fan Yang Ran Meng Da-Long Zhu Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
description	Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are a new type of drug for the treatment of diabetes, and they have been proven to have a good hypoglycemic effect. Several lines of clinical evidence have shown that SGLT2 inhibitors can significantly reduce the risks of atherosclerosis, hospitalization for heart failure, cardiovascular death, and all-cause mortality and delay the progression of chronic kidney disease. Because of the protective effects of SGLT2 inhibitors on the heart and kidney, they are being studied for the treatment of heart failure and chronic kidney disease in patients without diabetes. Therefore, it is necessary for cardiologists, patients with diabetes, and nephrologists to fully understand this type of drug. In this review, we summarize the following three aspects of SGLT2 inhibitors: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety.
format	article
author	Fan Yang Ran Meng Da-Long Zhu
author_facet	Fan Yang Ran Meng Da-Long Zhu
author_sort	Fan Yang
title	Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
title_short	Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
title_full	Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
title_fullStr	Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
title_full_unstemmed	Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
title_sort	cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
publisher	KeAi Communications Co., Ltd.
publishDate	2020
url	https://doaj.org/article/7cdbba4d6c314a6a9f286fa7af3beceb
work_keys_str_mv	AT fanyang cardiovasculareffectsandmechanismsofsodiumglucosecotransporter2inhibitors AT ranmeng cardiovasculareffectsandmechanismsofsodiumglucosecotransporter2inhibitors AT dalongzhu cardiovasculareffectsandmechanismsofsodiumglucosecotransporter2inhibitors
_version_	1718391614042275840

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors

Ejemplares similares